Pharmena S.A. (PHR) — Cash Flow-to-Debt Ratio

Latest as of September 2025: -0.96x

Pharmena S.A. (PHR) has a Cash Flow-to-Debt Ratio of -0.96x as of September 2025, meaning its operating cash flow of zł-820.00K could theoretically repay -1% of its total liabilities (zł850.00K) in one year. Check total reinvestment intensity of Pharmena S.A. to assess the company's total reinvestment commitment from operating cash flow.

CF-to-Debt Ratio

-0.96x
Operating CF / Total Liabilities

Operating Cash Flow

zł-820.00K
PLN

Total Liabilities

zł850.00K
PLN

Data as of

Sep 2025
Most recent filing

Pharmena S.A. Cash Flow-to-Debt Ratio (2008–2024)

Historical debt coverage capacity for Pharmena S.A. across 17 annual periods. Also explore total assets of Pharmena S.A. for the complete picture of this company's asset base.

Annual Cash Flow-to-Debt Ratio for Pharmena S.A. (2008–2024)

Year-by-year debt coverage analysis for Pharmena S.A.. For market capitalisation and broader financial context, see PHR stock market capitalisation.

Year CF-to-Debt Ratio Operating CF (PLN) Total Liabilities YoY Change
2024 -2.29x zł-2.53 Million zł1.11 Million ▼ -113.2%
2023 17.33x zł33.03 Million zł1.91 Million ▲ +18355.7%
2022 0.09x zł1.82 Million zł19.37 Million ▲ +147.4%
2021 -0.20x zł-3.23 Million zł16.27 Million ▲ +0.2%
2020 -0.20x zł-2.24 Million zł11.30 Million ▲ +89.8%
2019 -1.95x zł-13.15 Million zł6.74 Million ▼ -362.6%
2018 0.74x zł3.61 Million zł4.87 Million ▲ +804.5%
2017 0.08x zł619.00K zł7.54 Million ▲ +172.1%
2016 -0.11x zł-950.00K zł8.34 Million ▲ +82.3%
2015 -0.64x zł-4.17 Million zł6.49 Million ▲ +57.7%
2014 -1.52x zł-5.75 Million zł3.78 Million ▲ +0.6%
2013 -1.53x zł-3.84 Million zł2.51 Million ▲ +1.5%
2012 -1.55x zł-4.05 Million zł2.61 Million ▼ -472.2%
2011 0.42x zł666.91K zł1.60 Million ▲ +135.2%
2010 -1.18x zł-1.08 Million zł912.97K ▼ -517.6%
2009 -0.19x zł-179.22K zł934.89K ▼ -333.0%
2008 -0.04x zł-32.56K zł735.26K
Cash Flow-to-Debt Ratio = Operating Cash Flow / Total Liabilities. Higher is better for debt service capacity.